Results 101 to 110 of about 3,492,883 (216)

LMNA Reduced Acquired Resistance to Erlotinib in NSCLC by Reversing the Epithelial–Mesenchymal Transition via the FGFR/MAPK/c-fos Signaling Pathway

International Journal of Molecular Sciences, 2022
For patients exhibiting non-small-cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations, epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are a first-line treatment.
Chunsheng Hu, Anting Zhou, Xin Hu, Yu-heng Xiang, Mengjun Huang, Jiuhong Huang, Donglin Yang, Yan Tang   +7 more
semanticscholar   +1 more source

A Phase 1/2 Trial of Ruxolitinib and Erlotinib in Patients with EGFR -Mutant Lung Adenocarcinomas with Acquired Resistance to Erlotinib [PDF]

Journal of Thoracic Oncology, 2017
Resistance to EGFR tyrosine kinase inhibitors develops in patients with EGFR-mutant lung cancers. New treatments are needed to address resistance not mediated by EGFR T790M; preclinical evidence suggests that the Janus kinase/signal transducers and activators of transcription signaling pathway is important in acquired resistance to EGFR-directed ...
Helena A, Yu, Leslie, Perez, Qing, Chang, Sizhi P, Gao, Mark G, Kris, Gregory J, Riely, Jacqueline, Bromberg   +6 more
openaire   +2 more sources

Mitochondrial reprogramming in lung cancer: a therapeutic vulnerability and a strategy for reversing drug resistance

The Journal of Pathology, Volume 269, Issue 2, Page 149-163, June 2026.
Abstract The conceptualization of mitochondria, previously restricted to their function as cellular ‘powerhouses’, has evolved to recognize their function as central coordinating hubs for the orchestration of cancer cell metabolism, signaling, and fate determination.
Woo Hyun Park
wiley   +1 more source

Luteolin enhances erlotinib’s cell proliferation inhibitory and apoptotic effects in glioblastoma cell lines

Frontiers in Pharmacology, 2022
The epidermal growth factor (EGFR) receptor is frequently overexpressed in glioblastoma multiforme IV (GBM). Increased expression of EGFR leads to increased proliferation, decreased apoptosis, and increased resistance to chemotherapeutic agents.
Erika Powe, Daniel Parschauer, Jessica Istifan, Stacy Lin, Huanyun Duan, Rebecca Gryka, Denise Jean-Louis, Amit K. Tiwari, Amit K. Tiwari, Amit K. Tiwari, Samson Amos   +10 more
doaj   +1 more source

Inhibition of Hedgehog signaling sensitizes NSCLC cells to standard therapies through modulation of EMT-regulating miRNAs [PDF]

, 2013
Background Epidermal growth factor receptor- tyrosine kinase inhibitors (EGFR-TKIs) benefit Non-small cell lung cancer (NSCLC) patients, and an EGFR-TKIi erlotinib, is approved for patients with recurrent NSCLC.
Ahmad, Aamir, Bao, Bin, Gadgeel, Shirish M, Ginnebaugh, Kevin R, Li, Yiwei, Maitah, Ma\u27in Y, Sarkar, Fazlul H   +6 more
core   +2 more sources

Boron Neutron Capture Therapy at a Crossroads: Translational Gap and Emerging Delivery Agents

Chemistry – A European Journal, Volume 32, Issue 17, 5 May 2026.
This review surveys recent advances in boron delivery agents for BNCT, emphasizing the shift from classical small molecules to multifunctional nanocarriers and theranostic systems. By integrating targeting, imaging, and therapy, next‐generation boron compounds aim to bridge the gap between (bio)chemical innovation and clinical translation.
Christoph Selg, Evamarie Hey‐Hawkins
wiley   +1 more source

Programmable biomaterials for dynamic and responsive drug delivery [PDF]

, 2016
Biomaterials are continually being designed that enable new methods for interacting dynamically with cell and tissues, in turn unlocking new capabilities in areas ranging from drug delivery to regenerative medicine. In this review, we explore some of the
Almquist, BD, Kiani, MT, Stejskalova, A
core   +1 more source

The newfound relationship between extrachromosomal DNAs and excised signal circles

FEBS Letters, Volume 600, Issue 9, Page 1265-1287, May 2026.
Extrachromosomal DNAs (ecDNAs) contribute to the progression of many human cancers. In addition, circular DNA by‐products of V(D)J recombination, excised signal circles (ESCs), have roles in cancer progression but have largely been overlooked. In this Review, we explore the roles of ecDNAs and ESCs in cancer development, and highlight why these ...
Dylan Casey, Zeqian Gao, Joan Boyes
wiley   +1 more source

Stanniocalcin 2‐Induced Autophagy Confers Resistance of Lung Cancer Cells to EGFR Inhibition via the ERK/Beclin 1 Signaling

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Background Although epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) are effective in treating NSCLC with EGFR mutations, the development of resistance limits their long‐term efficacy. Autophagy has been implicated as a potential mechanism behind this acquired resistance.
Yi‐Nan Liu, Yi‐Ling Chen, Meng‐Feng Tsai, Shang‐Gin Wu, Tzu‐Hua Chang, Tzu‐Hsiu Tsai, Jin‐Yuan Shih   +6 more
wiley   +1 more source

Emerging role of nuclear factor erythroid 2-related factor 2 in the mechanism of action and resistance to anticancer therapies [PDF]

, 2019
Nuclear factor E2-related factor 2 (NRF2), a transcription factor, is a master regulator of an array of genes related to oxidative and electrophilic stress that promote and maintain redox homeostasis. NRF2 function is well studied in in vitro, animal and
Deeni, Yusuf Y., Kankia, Ibrahim H., Langdon, Simon P., Paramasivan, Poornima   +3 more
core   +3 more sources